ReWalk Robotics Company Profile
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.
ReWalk Robotics
ReWalk Robotics, Inc.200 Donald Lynch Boulevard
Marlborough, Massachusetts, 01752
United States
1 508 251-1154
ReWalk Robotics News & Resources
ReWalk Robotics Takes Steps Towards Next-Generation Exoskeleton
December 7, 2023
New prototype integrates advanced sensing technologies and AI to enable more autonomous decision making.
New Bill Greenlights Exoskeletons for Vets
November 20, 2023
ReWalk Robotics supports legislation enhancing vet access to powered exoskeletons.
ReWalk Comes Out on Top in German Legal Case
November 14, 2022
ReWalk was elated to hear that health insurance provider BARMER had accepted the decision of a German court that exoskeletons are considered as direct disability compensation.
Cybernetix Ventures Launches $50M Fund for Robotics, Automation, and AI Startups
May 4, 2022
Cybernetix Ventures was created by MassRobotics co-founder Fady Saad and sensor industry executive Mark Martin and already has $25 million committed. It said it is the first of its kind.
Cogniteam to Lead Israel Innovation Authority’s $20M Consortium for Human-Robot Interaction
April 13, 2022
Cogniteam, whose Nimbus platform is designed to work with ROS and help developers accelerate time to market, will lead an effort to advance robots' social capabilities.
ReWalk Robotics, Imago Rehab Join Massachusetts Funded Wearables Research With Harvard, Boston University
March 4, 2022
Massachusetts has awarded a grant worth $3 million to collaborators at Harvard, Boston University, ReWalk Robotics, and Imago Rehab to develop and commercialize assistive robotics.
ReWalk ReBoot Soft Exosuit Receives FDA Breakthrough Device Designation
November 7, 2021
The FDA's classification of the ReBoot orthotic exosuit as a "breakthrough device" will help ReWalk Robotics move forward with regulatory approvals and commercialization.